反应 #640527

ord-dde274e722b0409d87706d81630193ab

反应方程式

N#CCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine
N#CCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-Benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine
[Al+3].[H-].[H-].[H-].[H-].[Li+]
LiAlH4
C1CCOC1
THF
C1CCOC1
THF
OCCCNc1nonc1-c1nc2ccccc2[nH]1
title compound
OCCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-Benzimidazol-2-yl)-furazan-3-yl-N-(3-hydroxypropyl)-amine

反应条件

详细条件
See reaction.notes.procedure_details.

后处理

  1. 1
    其他is quenched by careful addition of aqueous saturated solution of sodium sulphate
  2. 2
    过滤The suspension is filtered
  3. 3
    其他the filtrate evaporated to dryness
  4. 4
    其他Crystallization
  5. 5
    workup.ADDITIONby addition of hexane

实验过程

A solution of 4-(1H-benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine (0.272 g, 0.947 mmol, Example 6a) in THF (5 ml) is added dropwise at 0° C. to an efficiently stirred suspension of LiAlH4 (0.054 g, 1.42 mmol) in THF (5 ml). After stirring for 16 hours at room temperature the mixture is quenched by careful addition of aqueous saturated solution of sodium sulphate. The suspension is filtered and the filtrate evaporated to dryness. Crystallization by addition of hexane yields the title compound in pure form. 1H-NMR (400 MHz, d6-DMSO): 13.6 (s, 1H); 7.66 (m, 2H); 7.31 (m, 2H); 6.92 (t, 1H); 4.61 (m, 1H); 3.51 (m, 2H); 3.39 (m, 2H); 1.81 (m, 2H).

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: USRE042890E1uspto-grants-2011_11